Skip to main
OABI
OABI logo

OmniAb Inc (OABI) Stock Forecast & Price Target

OmniAb Inc (OABI) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OmniAb Inc. demonstrated positive financial momentum in its 1Q25 results, reporting revenues of $4.2 million, which reflects a 9% year-over-year increase, alongside reduced net losses of $18.2 million, improving from a loss of $19.0 million in the previous year. The company's solid balance sheet further strengthens its prospects, providing a firm foundation for sustained growth. Additionally, anticipated near- and long-term R&D catalysts are expected to drive continued upward momentum for the stock, aligning with the company's commitment to advancing its innovative therapeutic antibody discovery technologies.

Bears say

OmniAb Inc. experienced a decline in its stock value following its November 2022 merger with Avista Public Acquisition Corporation II, likely due to negative market conditions impacting both similar mergers and established biotechnology companies. The company's guidance on operating cash burn indicates a persistent concern about financial sustainability, as it expects lower cash burn in 2023 compared to the anticipated burn in 2024. These factors, combined with overall market dynamics, contribute to a negative outlook for OmniAb's stock performance.

OmniAb Inc (OABI) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OmniAb Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OmniAb Inc (OABI) Forecast

Analysts have given OmniAb Inc (OABI) a Strong Buy based on their latest research and market trends.

According to 3 analysts, OmniAb Inc (OABI) has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OmniAb Inc (OABI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.